Skip to content

TTRX TTRX Total Equity

Total Equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$2.06B-74.0%
Journey Medical Corporation logo
Journey Medical CorporationDERM
$30.83M+43.1%
PTH
Pelthos Therapeutics Inc.PTHS
$35.1M+937%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$456.23M-35.1%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$189.65M+32.9%

Other financials

Income statement

See full
Operating income-$1.2M-224%
Net income-$971.0K-196%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$11.2M+613%
Total debt$6.0M
Total assets$18.6M

Cash flow

See full
Operating cash flow-$1.6M-448%

Valuation

See full
Market cap$217.45M-17.7%
Enterprise value$212.24M

Returns & leverage

See full
Return on equity-118.8%
Debt / equity
Current ratio2.2×

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TTRX's total equity?
TTRX (TTRX) reported total equity of $6.12M in Q1 2026.
How has TTRX's total equity changed year-over-year?
TTRX's total equity increased by 647.2% year-over-year, from $818.71K to $6.12M.
What is the long-term trend for TTRX's total equity?
Over 2 years (2023 to 2025), TTRX's total equity has grown at a 639.2% compound annual growth rate (CAGR), from $85.77K to $4.69M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.